Randomised controlled trialcited by the Tayebat archiveabstract only checked A-UPF-16 standard review

Emulsifier CMC in a small human trial

Randomized Controlled-Feeding Study of Dietary Emulsifier Carboxymethylcellulose Reveals Detrimental Impacts on the Gut Microbiota and Metabolome.

Overview

Chassaing B et al.. Gastroenterology 2022 · PMID 34774538 · DOI 10.1053/j.gastro.2021.11.006

Seven people eating CMC for 11 days had changes in gut bacteria and mild discomfort.

Does the study support the specific claim? Partly · Methodological quality: moderate

Study explained simply

What did the researchers want to find out?: Does CMC affect the gut in healthy humans?
How was the study done?: Double-blind controlled feeding study, 11 days.
How many people, animals or samples were studied?: 16 (9 control, 7 CMC); Healthy adults
What was actually found?: CMC modestly increased postprandial abdominal discomfort, reduced microbiota diversity, reduced faecal SCFAs and free amino acids; 2 CMC subjects showed microbiota encroachment into inner mucus.
How large was the observed effect?: Not applicable
What do the results mean in everyday life?: Early human signal.
What are the study's limitations?: Very small; Short; High dose; Surrogate outcomes
What does it say about Elawady's specific claim?: Supports C-UPF-06.
Do the results apply to Germany and Europe?: High.
What can explicitly not be concluded from this study?: Disease risk.

Authors: Chassaing B, Compher C, Bonhomme B, Liu Q, Tian Y, Walters W, Nessel L, Delaroque C, Hao F, Gershuni V, Chau L, Ni J, Bewtra M, Albenberg L, Bretin A, McKeever L, Ley RE, Patterson AD, Wu GD, Gewirtz AT, Lewis JD
Journal: Gastroenterology
Year: 2022
Identifier: PMID 34774538 DOI 10.1053/j.gastro.2021.11.006 · PMC9639366
Verification: verified – PubMed E-utilities efetch, 2026-10-25
Retracted: no
Corrections: none
Extent checked: abstract only
Conflicts of interest and funding: One author with pharma/industry consulting; NIH grants

Does CMC affect the gut in healthy humans?

Study design: Randomised controlled trial – Double-blind controlled feeding study, 11 days.
Population: Healthy adults
Country: USA
Period: not stated in abstract
Sample size: 16 (9 control, 7 CMC)
Inclusion and exclusion criteria: not stated in abstract

Results: CMC modestly increased postprandial abdominal discomfort, reduced microbiota diversity, reduced faecal SCFAs and free amino acids; 2 CMC subjects showed microbiota encroachment into inner mucus.
Absolute risks: not applicable
Authors' conclusion: Broad CMC use may contribute to chronic inflammatory diseases.

Low precision.

Supports C-UPF-06.

None.

High.

Preliminary human support.

Multidimensional assessment
Multidimensional assessment
Authenticity of the source	verified
Methodological quality	moderate
Risk of bias	some concerns
Precision of results	low
Directness	indirect
Reproducibility	not replicated
Consistency with the overall evidence	unknown
Regional transferability	high
Adequacy of the interpretation (by the archive)	not applicable

Clinical relevance.

Note: according to the archive, the studies were compiled by the archive operators. Whether Dr. Elawady himself cited this study is not established.

What the archive says about the study: Listed in the archive bibliography only (no archive interpretation card).
A. What was actually studied?: CMC in humans.
B. What did the authors find?: As above.
C. What conclusions do the authors themselves draw?: As above.
D. What does the archive derive from it?: Supports emulsifier mechanism.
E. Is this derivation scientifically justified?: Consistent; tiny study.
Adequacy of the interpretation (by the archive): not applicable